Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-30

Study Completion Date

2040-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial adopts an observational research method to conduct annual follow-up and monitoring of patients receiving treatment with Inaticabtagene Autoleucel Injection after its commercialization, in order to evaluate the delayed adverse events of Inaticabtagene Autoleucel Injection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

NCT06136364

T-lymphoblastic Lymphoma T-ALL

RECRUITING PHASE1

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy Multiple Myeloma DLBCL +2 more

ENROLLING_BY_INVITATION PHASE2

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

NCT06777264

Acute Lymphoblastic Leukemia B Cell ALL

NOT_YET_RECRUITING PHASE2

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

NCT04796441

AML

UNKNOWN NA

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07234045

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Relapsed/Refractory B-cell ALL

NOT_YET_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients treated with Inaticabtagene Autoleucel Injection (including registered clinical trial patients with different indications of this product and commercialized patients after market launch), would be included in this program for a maximum of 15 years of long-term follow-up (LTFU), and an informed consent form must be signed again. The research period was 15 years after Inaticabtagene Autoleucel infusion. The patient was followed up once a year for 15 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

B-cell Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inaticabtagene autoleucel Injection

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CNCT19

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Agree to sign an informed consent form for long-term follow-up studies.
2. Registered clinical trial patients with different indications for this product who have received at least one infusion of Inaticabtagene Autoleucel Injection in the past, as well as post market commercialized patients.